E2F2转录因子通过miR-34a-5p调控肝胆代谢促进胆汁淤积性MASH表型
研究在胆碱缺乏高脂饮食或DEN-HFD诱导的MASH小鼠及两个经活检证实的MASLD患者队列中,探讨E2F2在MASLD相关胆汁淤积中的作用及miRNA机制。E2f2缺失增加胆固醇、磷脂酰胆碱和胆汁酸的合成与排泄,减少肝脏储存并增加粪便排出,减轻炎症和纤维化,预防MASH;E2F2过表达上调miR-34a-5p,miR-34a-5p模拟物可消除E2f2缺失的保护作用。
要点
- E2f2缺失促进 biliary lipid 合成与排泄,减少肝脏脂质储存,减轻MASH炎症和纤维化。
- E2F2过表达上调miR-34a-5p,miR-34a-5p模拟物消除E2f2缺失的保护效应。
- 晚期纤维化、炎症、脂肪变评分、胆石症及血清胆汁酸和胆汁脂质升高的患者肝内miR-34a-5p水平升高。
核心结论
- E2F2缺失通过调控miR-34a-5p预防胆固醇蓄积、纤维化和炎症,从而抵御MASH和胆汁淤积,可能为胆汁淤积性MASH患者提供治疗获益。
研究设计与样本
- E2f2敲除(E2f2-/-)和野生型(WT)小鼠分别喂食胆碱缺乏高脂饮食(ChD-HFD)或注射二乙基亚硝胺后喂食高脂饮食(DEN-HFD)以诱导MASH。
- 通过AAV8在肝脏过表达E2F2,通过胆管结扎或富含3,5-二乙氧基羰基-1,4-二氢可力丁的饮食诱导胆汁淤积,并进行microRNA测序。
- 使用两个经活检证实的MASLD患者队列。
主要发现
- E2F2缺失增加胆固醇、磷脂酰胆碱和胆汁酸的合成与排泄,减少其在肝脏中的储存并增加粪便中的存在。
- E2F2缺失伴随胆汁脂质代谢相关基因表达增加、炎症和纤维化减轻及独特miRNA谱的产生,从而预防MASH。
- 肝脏特异性诱导E2F2在体内阻碍胆汁脂质代谢转录程序并上调miR-34a-5p,而miR-34a-5p在E2f2-/-小鼠中下调。
- 使用miR-34a-5p模拟物后,E2f2-/-小鼠中观察到的保护效应消失。
- 晚期纤维化、炎症、脂肪变评分、胆石症及血清胆汁酸和胆汁脂质升高的患者肝内miR-34a-5p水平升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects a heterogeneous group of patients. Among them, those with a cholestatic profile show worse outcomes. Here, we investigated whether E2F2 is involved in MASLD-associated cholestasis and, if so, the role of miRNAs. APPROACH AND RESULTS: E2f2 -knockout ( E2f2-/- ) and wild-type (WT) mice were fed a choline-deficient high-fat diet (ChD-HFD) or an HFD after injection of diethylnitrosamine (DEN-HFD) to induce metabolic dysfunction-associated steatohepatitis (MASH). E2F2 was overexpressed in the liver by AAV8. Cholestasis was induced by bile duct ligation or by a 3,5-diethoxycarbonyl-1,4-dihydrocollidine-enriched diet. microRNA sequencing was performed. Two biopsy-proven MASLD patient cohorts were used. E2F2 deficiency resulted in increased synthesis and excretion of cholesterol, phosphatidylcholine, and bile acids, reducing their storage in the liver while increasing their presence in feces. This was consistent with increased expression of genes involved in biliary lipid metabolism, reduced inflammation and fibrosis, and the generation of a distinct miRNA profile, thereby preventing MASH. Liver-specific induction of E2F2 in vivo hampered the transcriptional program involved in biliary lipid metabolism and upregulated miR-34a-5p, which was downregulated in E2f2-/- mice. The protective effects observed in E2f2-/- mice were lost when a miR-34a-5p mimic was used. Hepatic miR-34a-5p levels were elevated in patients with advanced fibrosis, inflammation, steatosis score, cholelithiasis, and increased serum bile acids and biliary lipids. E2f2 deficiency conferred protection against cholestatic liver injury. CONCLUSIONS: E2F2 deficiency protects against MASH and cholestasis, preventing cholesterol accumulation, fibrosis, and inflammation through modulation of miR-34a-5p. This could provide therapeutic benefits for patients with cholestatic MASH.
引用
- Apodaka-Biguri M, Simão AL, González-Romero F, et al. E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p. Hepatology. 2025. PMID: 40720724. doi:10.1097/HEP.0000000000001461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。